Biotech ace joins Abzena
30.03.2015 - Life Sciences company Abzena has appointed biotechnology expert Jim Mills as its Vice President of Technical Operations. The Cambridge-based company provides services and technologies that enable the development of biopharmaceutical products.
John brings a wealth of experience in the fields of biotechnology and biochemistry. Before joining Abzena in March, he held the position of CEO of Cantab Biopharmaceuticals, which he joined in 1997, initially to work in process development. Whilst at Cantab he took on roles of increasing levels of responsibility in biopharmaceutical manufacturing before becoming Director of Operations following the acquisition of Cantab by Xenova in 2007. In 2010, he took the helm as CEO when the company was taken over by Celtic Pharma Holdings.
“We are delighted to welcome Jim to Abzena and I look forward to working with him as the Company continues its commercial and corporate development,” said John Burt, CEO of Abzena.
In his new position as Vice President of Technical Operations, Jim will take on a lead role in the development of the Group’s strategy to support its partners’ access to Abzena’s technologies for biopharmaceutical development, as well as providing support for the commercial activities of the group.http://www.european-biotechnology-news.com/people/bio-people/2015/jim-mills.html